Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ferring Pharmaceuticals
Destiny’s Phase IIb clinical study of lead asset XF-73 in the prevention of post-surgical bacterial infections got a boost from trial protocol amendments agreed with the FDA.
Using live bacteria modified to deliver specific proteins to treat cancer is to be explored by the Swiss start-up, T3 Pharmaceuticals, which has garnered a large third round of funding from a European corporate VC, institutional and private investors, to advance its lead candidate into clinical trials.
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
Last month a drug for the prevention of uterine haemorrhage became the first product to be approved under a novel scheme designed to speed up access to medicines in low and middle-income countries, particularly those in sub-Saharan Africa.
- Specialty Pharmaceuticals
- Drug Discovery Tools
- Other Names / Subsidiaries
- BioSurface Engineering Technologies, Inc. (BioSET)
- Cytokine PharmaSciences, Inc. (Subsidiary: Controlled Therapeutics Ltd.)
- Ferring Pharmaceuticals
- Rebiotix, Inc.